Objective:

The aim of this study was to evaluate the experience of the use of the MitraClip device in terms of mortality, complications, mitral valve regurgitation reduction, and variations in left ventricle echocardiographic parameters.

Material and methods:

All patients included in the study were treated with the MitraClip device, assessed and considered to be high risk by the Heart Team. Follow-up was conducted 3-9 months after the procedure with transthoracic and transesophageal echocardiography.

Results:

Thirty-three patients were recruited from three medical centers in Mexico. After the procedure, 76% of patients were considered to have had a successful treatment, and during follow-up, 70% remained in this category, whereas only 6% of patients continued to experience mitral valve regurgitations still. Seven patients died, two of them during follow-up and five more dying from postoperative complications. The overall survival was 17.2 ± 1.3 months (CI 14.6-19.9). During the procedure, one detachment and one partial detachment of the device occurred. The procedural success was similar to the one reported in the EVEREST I study and the 2016 TVT registry. In this study, it was found that only one patient had a recurrence of severe MR. It has been described that The Society of Thoracic Surgeons (STS) risk scale and mortality had a strong relationship, which matched the results of this study. In this research, no complications were found, as seen in other trials, such as stroke or dialysis requirements.

Conclusions:

In this population, treatment with the MitraClip device improved the functional class and had few adverse events, signifying this treatment is an achievable option.

        · abstract in Spanish     · text in English     · English ( pdf )